Benefits
Supports a normal inflammatory response in laboratory and animal work
The most studied activity is on inflammation signalling, but the evidence is preclinical. In cell and animal studies BCP lowered markers such as TNF-alpha and IL-6 and reduced a paw-swelling response in mice, an effect that disappeared in mice lacking the CB2 receptor. These are laboratory and animal findings, not measured health outcomes in people.
Selective CB2 cannabinoid-receptor activity without a high
In laboratory testing BCP binds the CB2 receptor and acts as a functional agonist, while it does not meaningfully activate the CB1 receptor that produces cannabis intoxication. This is why it is described as a non-psychoactive dietary cannabinoid. The CB2 activity is a laboratory mechanism, not a proven human health effect.
Eating-behavior score in one human trial
In an 8-week randomized placebo-controlled trial, 52 women with obesity who met a food-addiction cut-off took a 100 mg softgel or placebo daily. The food-addiction score fell more with BCP than placebo. There was no effect on body weight, body composition, appetite, dietary intake or mental-health scores. One small short trial of a behavioral score, not weight loss.
Digestive comfort in one human trial
In an 8-week randomized placebo-controlled trial, 66 people with Helicobacter pylori infection took 126 mg a day of BCP or placebo. The bacteria were not cleared in either group and a breath-test marker did not change, but nausea and upper-abdominal discomfort improved and one inflammatory marker (IL-1beta) fell in the BCP group. Infection needs medical care.
Joint comfort in a combination-product trial
A 45-day controlled trial in 38 people with knee osteoarthritis compared a hemp-seed-oil supplement with the same oil plus terpenes including BCP, myrcene and ginger extract. The terpene combination improved pain and function scores more than the oil alone. Because several ingredients were combined, the result cannot be assigned to BCP by itself.
Pain and mood behaviors in animal studies
In rodent studies, oral BCP reduced pain behaviors and depression-like and anxiety-like behaviors, and lowered substance P and cytokines such as IL-1beta, IL-6 and TNF-alpha; the behavioral effects were blocked by a CB2 antagonist, pointing to CB2 involvement. These outcomes were measured in mice, not in people.
Metabolic measures in animal studies
In mice fed a high-fat diet, BCP reduced liver fat and improved lipid and glucose measures, with activation of the AMPK energy-sensing pathway reported. Reviews link these effects to CB2 and PPAR-gamma signalling. All of this is animal and laboratory work; BCP has not been shown to change weight, blood sugar or blood fats in people.
Mechanism of action
Selective CB2 receptor activation
BCP binds the CB2 cannabinoid receptor and acts as a functional agonist in laboratory assays, inhibiting adenylate cyclase inside cells. CB2 receptors sit mainly on immune cells, so activating them is studied as a way to influence immune and inflammatory signalling without the CB1-driven psychoactive effects of cannabis. Shown in cell studies.
Dampens inflammatory signalling in laboratory models
In cell and animal experiments BCP lowered bacterial-toxin-driven production of inflammatory cytokines and reduced signalling through pathways such as NF-kB and MAP kinases. This is the proposed basis for its anti-inflammatory activity, but it has been demonstrated in laboratory and animal systems rather than as a clinical outcome in people.
Limited oral bioavailability
BCP is a fat-soluble sesquiterpene that is poorly soluble in water, and much of a swallowed dose is broken down by first-pass metabolism before reaching the bloodstream. Researchers are testing self-emulsifying and nanoparticle delivery systems to raise absorption. This limited bioavailability is one reason animal findings may not carry over to ordinary supplement use.
Clinical trials
Laboratory and animal study characterizing (E)-beta-caryophyllene as a selective CB2-receptor agonist, with human blood-cell experiments and a mouse paw-inflammation model (Gertsch et al. 2008, Proc Natl Acad Sci U S A)
No human efficacy participants: human monocytes and blood cells tested in vitro, plus normal mice and mice lacking the CB2 receptor.
BCP bound the CB2 receptor (about 155 nM) and behaved as a functional agonist without meaningful CB1 activity. In human cells it lowered toxin-induced inflammatory cytokine signalling, and oral BCP at 5 mg/kg reduced a paw-swelling response in normal mice but not in mice without CB2 receptors. This is mechanism and animal work, not a human health outcome.
Randomized, double-blind, placebo-controlled trial of a 100 mg/day BCP softgel for 8 weeks in women with obesity meeting a food-addiction cut-off (Alizadeh et al. 2022, Appetite)
52 women with obesity and a Yale Food Addiction Scale score of 3 or more (26 BCP, 26 placebo).
The food-addiction score fell more with BCP than placebo (corrected p = 0.05). Serum orexin-A fell within the BCP group but the between-group difference was not significant. There was no significant effect on body weight, body composition, appetite, eating behavior, dietary intake or mental-health scores. Small and short.
8-week randomized, double-blind, placebo-controlled trial of 126 mg/day BCP in patients with Helicobacter pylori infection, with endoscopy, urea breath test and serum cytokines (Shim et al. 2019, Korean J Gastroenterol)
66 patients with Helicobacter pylori infection (33 BCP, 33 placebo).
The infection was not eradicated in either group and the urea-breath-test and Sydney scores did not change. Nausea (p = 0.025) and epigastric pain (p = 0.018) improved and serum IL-1beta fell (p = 0.038) in the BCP group. The authors framed it as a possible supplementary measure for digestive symptoms, not a treatment for the infection.
45-day controlled trial comparing a hemp-seed-oil supplement with the same oil plus terpenes including BCP, myrcene and ginger extract in knee osteoarthritis (Farì et al. 2023, Medicina (Kaunas))
38 adults with knee osteoarthritis split into two supplement groups.
Pain and function scores improved in both groups, with a greater improvement in pain, KOOS and Oxford Knee Score in the group taking the terpene combination. Because the product combined several ingredients, the result cannot be attributed to BCP alone, and the comparator still contained hemp-seed oil. Small and open to bias.
Animal study of chronic oral BCP (10 mg/kg) in streptozotocin-induced diabetic mice, measuring pain behaviors, mood-related behaviors and cytokines (Aguilar-Avila et al. 2019, J Med Food)
No human participants: female BALB/c diabetic mice.
Oral BCP lowered blood glucose, reduced pain responses and tail-suspension immobility, and lowered substance P and the cytokines IL-1beta, IL-6 and TNF-alpha. The authors suggest dietary BCP may reduce diabetes-related nerve pain and low mood. These are animal findings only and do not establish an effect in people.
Animal study of BCP (50 mg/kg) in mice across standard anxiety and depression behavioral tests, with a CB2 antagonist control (Bahi et al. 2014, Physiol Behav)
No human participants: adult mice.
BCP increased time in the open parts of a maze and the center of an open field, reduced marble burying, and lowered immobility in tail-suspension and forced-swim tests, consistent with anxiety- and depression-reducing behavior. A CB2 antagonist blocked the effect, implicating the CB2 receptor. Behavior in mice, not a human outcome.